LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals

LifeSci Advisors Initiates Coverage of Oramed Pharmaceuticals 
NEW YORK, NY -- (Marketwired) -- 03/20/14 --   LifeSci Advisors, LLC
and Oramed Pharmaceuticals (NASDAQ: ORMP) 

--  Oramed's Oral Insulin Development Program is in Phase II for the
    Treatment of Diabetes
--  Report Available for Download at

LifeSci Advisors, LLC, a leading provider of investment research and
investor relations services in the life sciences sector, today
announced that it has initiated coverage of Oramed Pharmaceuticals
(NASDAQ: ORMP), a pharmaceutical company developing a platform
technology for the oral delivery of proteins and peptides. The
Company's proprietary protein oral delivery (POD(TM)) technology
protects proteins during gastrointestinal transport and facilitates
absorption into the bloodstream. The Company's lead candidate is
ORMD-0801, an oral insulin product that is being tested in different
populations of diabetes patients. Oramed is also developing
ORMD-0901, an oral version of the GLP-1 agonist exenatide. Oral
insulin delivery is similar to pancreatic insulin secretion because
after absorption in the intestine it goes directly to the liver, more
closely mimicking the natural process than insulin injections. Two
Phase II trials with ORMD-0801 are expected to launch in 2014.  
"Oramed is leveraging its technology platform to develop an oral
insulin product for diabetes," said Andrew I. McDonald, Ph.D.,
Founding Partner at LifeSci Advisors. "If the protein oral delivery
technology platform is shown to be a safe and effective way to
deliver insulin, it has the potential to improve compliance and
quality of life by reducing injections for diabetes patients." 
In January 2014, Oramed announced positive topline results from a
randomized, placebo-controlled Phase IIa trial of ORMD-0801 in type 2
diabetics. The results indicated that ORMD-0801 was safe and well
tolerated with no serious adverse events (AEs) in the study. Oramed
is scheduled to present more detailed data from the trial at the 2014
Diabetes Summit on April 24th in Cambridge, MA. Oramed is also
expanding the application of their POD(TM) technology for oral
delivery of the GLP-1 receptor agonist exenatide. The Company is
planning to launch a
n ex-US Phase Ib trial in the second quarter of
2014, while concurrently completing 90-day preclinical toxicology
studies intended to pave the way to commencement of a US-based Phase
IIb trial that is expected to start in the first half 2015. 
In a 41 page Initiation Report by LifeSci Advisors, we explain the
development path plus detailed clinical and preclinical data for
Oramed's oral insulin and oral exenatide programs. The report details
Oramed's clinical development strategy for type 1 and type 2 diabetes
mellitus. We examine the treatment landscape and competition for
insulin, and critically examine competing products and development
Dr. McDonald's full Initiation Report is available to download at no
cost at the LifeSci Advisors website, In
addition to this Initiation Report, LifeSci Advisors will also
provide ongoing coverage and event-based research updates on the
Company as developments occur. 
The LifeSci Advisors research team is led by Dr. Andrew I. McDonald,
an industry veteran with more than 15 years of healthcare industry
experience. Prior to co-founding LSA, Dr. McDonald was the Senior
Biotechnology Analyst at Great Point Partners, a leading health care
investment firm with over $500 million under management. Before Great
Point, he was Co-Head of Healthcare Research and Lead Biotechnology
Analyst at ThinkEquity Partners, a boutique investment banking firm
focused on growth companies. Dr. McDonald holds a Ph.D. in organic
chemistry from the University of California, Irvine, and, earlier in
his career, worked as a medicinal chemist at both Pfizer and
About LifeSci Advisors: 
LifeSci Advisors (LSA) is a leading research firm and communications
consultancy dedicated to the life sciences industry. The firm
provides strategic counsel, customized marketing communications,
comprehensive research reports and investor relations services to
companies that specialize in the discovery, development and
commercialization of drugs, drug delivery systems, medical devices
and diagnostics. To learn more about LSA, visit the company's
Important Disclosures: 
The research report described in this press release is not intended
as an offering, recommendation, or a solicitation of an offer to buy
or sell securities. The securities discussed in LSA research reports
may be unsuitable for some investors depending on their specific
investment objectives, financial status, risk profile, or particular
needs. Investors should consider LSA reports as only a single factor
in making their investment decisions and should not rely solely on
these reports in evaluating whether or not to buy or sell the
securities of the subject company. LifeSci Advisors has been
compensated by the company that is the subject of the report
described and future research reports, investor relations services,
and general consulting services. Please read each report's full
disclosures and analyst background on the LSA website,, before investing. LifeSci Advisors is not a
registered investment adviser or broker-dealer.  
Forward-looking statements:
 This press release contains
forward-looking statements subject to risks and uncertainties that
could cause actual results to differ materially from those projected.
These forward-looking statements represent LSA's judgment as of the
date of this release. LifeSci Advisors disclaims, however, any intent
or obligation to update these forward-looking statements. 
Media Contact:
Michael Rice
Phone: (646) 597-6979
Press spacebar to pause and continue. Press esc to stop.